Technology

Nanovesicle Delivery


Platform Delivery

The Genprex gene therapy platform consists of anti-cancer genes encapsulated in nanovesicles that are delivered intravenously. The Oncoprex TUSC2 gene is encapsulated in a positively charged nanovesicle that binds to actively replicating (and, therefore, negatively charged) cancer cells and then enters the cancer cell through selective endocytosis.

Scalable Manufacturing

The nanovesicle manufacturing methods we and our collaborators have developed have been optimized and are useful for a wide array of disease treatments.

Our nanovesicle delivery platform is applicable to delivery of a range of therapeutic and prophylactic plasmid DNAs and RNA interference constructs. The nanovesicle manufacturing methods we and our collaborators have developed have been optimized and are useful for a wide array of disease treatments. Our nanovesicles are clinically proven to deliver molecular kinase inhibitors effectively. Clinical outcomes demonstrated that the delivery system used in Oncoprex is well tolerated in humans and can safely deliver high therapeutic doses.

 
STAY IN THE KNOW WITH
EMAIL NEWS ALERTS
 
Don't miss out. Get our news delivered to your inbox.
 

 
close-link
 
Get Email News Alerts
 
close-link